Download
40478_2024_Article_1831.pdf 9,63MB
WeightNameValue
1000 Titel
  • Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma
1000 Autor/in
  1. Tsiami, Foteini |
  2. Lago, Chiara |
  3. Pozza, Noemi |
  4. PICCIONI, FEDERICA |
  5. Zhao, Xuesong |
  6. Lülsberg, Fabienne |
  7. Root, David |
  8. Tiberi, Luca |
  9. Kool, Marcel |
  10. Schittenhelm, Jens |
  11. Bandopadhayay, Pratiti |
  12. Segal, Rosalind |
  13. Tabatabai, Ghazaleh |
  14. Merk, Daniel |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-08-07
1000 Erschienen in
1000 Quellenangabe
  • 12(1):125
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s40478-024-01831-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304869/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Sonic hedgehog subgroup of medulloblastoma (SHH-MB) is characterized by aberrant activation of the SHH signaling pathway. An inhibition of the positive SHH regulator <jats:italic>Smoothened</jats:italic> (SMO) has demonstrated promising clinical efficacy. Yet, primary and acquired resistance to SMO inhibitors limit their efficacy. An understanding of underlying molecular mechanisms of resistance to therapy is warranted to bridge this unmet need. Here, we make use of genome-wide CRISPR-Cas9 knockout screens in murine SMB21 and human DAOY cells, in order to unravel genetic dependencies and drug-related genetic interactors that could serve as alternative therapeutic targets for SHH-MB. Our screens reinforce SMB21 cells as a faithful model system for SHH-MB, as opposed to DAOY cells, and identify members of the epigenetic machinery including DNA methyltransferase 1 (DNMT1) as druggable targets in SHH-dependent tumors. We show that <jats:italic>Dnmt1</jats:italic> plays a crucial role in normal murine cerebellar development and is required for SHH-MB growth in vivo. Additionally, DNMT1 pharmacological inhibition alone and in combination with SMO inhibition effectively inhibits tumor growth in murine and human SHH-MB cell models and prolongs survival of SHH-MB mouse models by inhibiting SHH signaling output downstream of SMO. In conclusion, our data highlight the potential of inhibiting epigenetic regulators as a novel therapeutic avenue in SMO-inhibitor sensitive as well as resistant SHH-MBs.</jats:p>
1000 Sacherschließung
lokal Cell Line, Tumor [MeSH]
lokal Medulloblastoma
lokal SHH pathway
lokal Cerebellar Neoplasms/pathology [MeSH]
lokal Medulloblastoma/pathology [MeSH]
lokal DNA (Cytosine-5-)-Methyltransferase 1/metabolism [MeSH]
lokal CRISPR-Cas Systems [MeSH]
lokal Hedgehog Proteins/genetics [MeSH]
lokal DNA (Cytosine-5-)-Methyltransferase 1/genetics [MeSH]
lokal Medulloblastoma/metabolism [MeSH]
lokal Smoothened Receptor/metabolism [MeSH]
lokal Hedgehog Proteins/metabolism [MeSH]
lokal Gene Knockout Techniques/methods [MeSH]
lokal DNMT1
lokal Humans [MeSH]
lokal Medulloblastoma/genetics [MeSH]
lokal Smoothened Receptor/genetics [MeSH]
lokal Cerebellar Neoplasms/genetics [MeSH]
lokal Animals [MeSH]
lokal Cerebellar Neoplasms/metabolism [MeSH]
lokal Mice [MeSH]
lokal Functional genomics
lokal Synergy
lokal Research
lokal Combinatorial treatment
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0009-0001-6070-0434|https://orcid.org/0000-0002-1317-7847|https://frl.publisso.de/adhoc/uri/UG96emEsIE5vZW1p|https://orcid.org/0000-0003-1210-3210|https://orcid.org/0000-0003-3007-7124|https://frl.publisso.de/adhoc/uri/TMO8bHNiZXJnLCBGYWJpZW5uZQ==|https://orcid.org/0000-0001-5122-861X|https://orcid.org/0000-0002-5983-3782|https://orcid.org/0000-0002-6557-5468|https://orcid.org/0000-0002-9168-6209|https://orcid.org/0000-0002-4175-4760|https://orcid.org/0000-0001-9850-8432|https://orcid.org/0000-0002-3542-8782|https://orcid.org/0000-0003-2935-6919
1000 Hinweis
  • DeepGreen-ID: 84ed18d9b92c419e8dbbe1bf4d14830f ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Wilhelm Sander-Stiftung |
  2. Deutsche Forschungsgemeinschaft |
  3. Dana-Farber Pediatric Low-Grad Glioma Program |
  4. Universitätsklinikum Tübingen |
1000 Fördernummer
  1. -
  2. -
  3. -
  4. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Wilhelm Sander-Stiftung |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Deutsche Forschungsgemeinschaft |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Dana-Farber Pediatric Low-Grad Glioma Program |
    1000 Förderprogramm -
    1000 Fördernummer -
  4. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Tübingen |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6518487.rdf
1000 Erstellt am 2025-07-05T11:35:32.118+0200
1000 Erstellt von 322
1000 beschreibt frl:6518487
1000 Zuletzt bearbeitet 2025-08-19T19:03:07.590+0200
1000 Objekt bearb. Tue Aug 19 19:03:07 CEST 2025
1000 Vgl. frl:6518487
1000 Oai Id
  1. oai:frl.publisso.de:frl:6518487 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source